503 related articles for article (PubMed ID: 28627443)
1. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Rostami G; Hamid M; Jalaeikhoo H
Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
[TBL] [Abstract][Full Text] [Related]
2. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
3. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
Pfirrmann M; Evtimova D; Saussele S; Castagnetti F; Cervantes F; Janssen J; Hoffmann VS; Gugliotta G; Hehlmann R; Hochhaus A; Hasford J; Baccarani M
J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
[TBL] [Abstract][Full Text] [Related]
4. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
[TBL] [Abstract][Full Text] [Related]
6. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Hanfstein B; Lauseker M; Hehlmann R; Saussele S; Erben P; Dietz C; Fabarius A; Proetel U; Schnittger S; Haferlach C; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
Haematologica; 2014 Sep; 99(9):1441-7. PubMed ID: 24837466
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Lucas CM; Harris RJ; Giannoudis A; Davies A; Knight K; Watmough SJ; Wang L; Clark RE
Haematologica; 2009 Oct; 94(10):1362-7. PubMed ID: 19713230
[TBL] [Abstract][Full Text] [Related]
9. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
10. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
Ercaliskan A; Eskazan AE
Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
[TBL] [Abstract][Full Text] [Related]
11. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
Su YJ; Kuo MC; Chen TY; Wang MC; Yang Y; Ma MC; Lin TL; Lin TH; Chang H; Teng CJ; Hsiao PC; Chen CC; Wang PN; Shih LY
Cancer Sci; 2022 Oct; 113(10):3518-3527. PubMed ID: 35869805
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
[TBL] [Abstract][Full Text] [Related]
13. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
14. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
Kjaer L; Skov V; Andersen MT; Aggerholm A; Clair P; Gniot M; Soeby K; Udby L; Dorff MH; Hasselbalch H; Pallisgaard N
Eur J Haematol; 2019 Jul; 103(1):26-34. PubMed ID: 30985947
[TBL] [Abstract][Full Text] [Related]
15. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
Qin YZ; Jiang Q; Jiang H; Lai YY; Shi HX; Chen WM; Yu L; Huang XJ
Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
[TBL] [Abstract][Full Text] [Related]
17.
Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
[TBL] [Abstract][Full Text] [Related]
18. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
Dulucq S; Etienne G; Morisset S; Klein E; Chollet C; Robbesyn F; Turcq B; Tigaud I; Hayette S; Nicolini FE; Mahon FX
Ann Hematol; 2019 May; 98(5):1159-1168. PubMed ID: 30798348
[TBL] [Abstract][Full Text] [Related]
19. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
20. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
Jain P; Kantarjian H; Patel KP; Gonzalez GN; Luthra R; Kanagal Shamanna R; Sasaki K; Jabbour E; Romo CG; Kadia TM; Pemmaraju N; Daver N; Borthakur G; Estrov Z; Ravandi F; O'Brien S; Cortes J
Blood; 2016 Mar; 127(10):1269-75. PubMed ID: 26729897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
